Registration & Payment

Registration Fee

Please select which registration you would like to purchase for the 2025 ISCBH Bone School below

Registration includes:

  • Lunch, dinner and tea and coffee breaks on all 3 days of course (as per the programme)
  • Attendance at all sessions and workshops
  • All course materials
  • Group dinners on Tuesday 27, Wednesday 28 and Thursday 29 May 2025

Fees are not subject to VAT

Full fee: €550 per person

Discounted fee: €425 per person

The discounted fee is available to trainees, allied health professionals, patient organisation representatives and attendees from low income countries.

To confirm your eligibility for the discounted fee you must send the eligibility form which can be downloaded HERE, completed by your Head of Department of Supervisor to events@theiscbh.org within 7 days of registering.

Accommodation

Accommodation needs to be booked and paid for in addition to the registration fee.

We have provisionally reserved all the rooms at Les Pensieres from Tuesday night through to Friday lunchtime (3 nights) so that all our faculty and delegates can arrive on Tuesday evening to be ready for a prompt start on Wednesday morning. It will be exclusively for our school. There are 59 rooms decorated in the spirit of a “family home”, each with a unique style, warmly and elegantly decorated. They all have full modern facilities including a flat-screen TV and Wi-Fi access. They also provide a laundry service.

Please select which nights you would like to book accommodation by selecting the dates and room type below – there are 17 standard rooms and 31 superior rooms available and these will be sold on a first come first served basis.

STANDARD ROOM

€155 per room, per night

single occupancy

includes breakfast, VAT and taxes

Number of nights required:*

SUPERIOR ROOM

€165 per room, per night

single occupancy

includes breakfast, VAT and taxes

Number of nights required:*

*If less than three nights required, please indicate which nights you require at checkout.

If you have made your own accommodation arrangements elsewhere please also indicate that at checkout.

Additional information

In addition to the details which you have already provided when you completed your application form, please could you also provide us with a mobile contact number and any dietary ar access requirements in the checkout.

Assistance letter for your visa application

Should you require a letter to assist with your visa application we can provide an assistance letter once we have received payment. We cannot issue a letter without payment as the French embassy requires a financial commitment to the event in order to issue a visa into France. This letter will only confirm your attendance at the Bone School. If you need us to include any specific information such as passport number or date of birth you will need to email the events team separately to request this.

Payment

Please review your selections in the basket and if all okay proceed to the checkout where you will be able to pay via card.

Insurance, Release and Waiver of Liability: In the unlikely case of cancellation of the event, the organisers shall not accept liability for any consequential loss and shall have no liability to reimburse any other costs that may have been incurred, including transport costs, accommodation etc. Delegates are encouraged to take out travel insurance when making travel and accommodation arrangements.

Photography, Audio Recording and Video Recording: Pictures and videos will be taken during the Bone School that might be used in ISCBH newsletters, websites, promotional material, social media, or other publications. As a registered delegate of this event, you agree to grant permission to ISCBH to use your photo and/or video. If you do not agree, please let the Event Manager know at the School or send an email to events@theiscbh.org

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our Rare Disease division is focused on generating scientific and technological breakthroughs for people living with a rare disease via the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders. Novo Nordisk employs about 50,800 people in 80 countries out of which 3.300 within rare disease.

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a heritage of 70+ years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa*, innovation and integrity.

*Harmony and loop among people.

Founded in 2007, Ascendis Pharma is applying its innovative TransCon™ technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we use our TransCon technologies to fulfill our mission of developing new and potentially best-in-class therapies that address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States.

Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases driven by pathologic mineralization and intimal proliferation which impact the vasculature, soft tissue and skeleton. We are initially focused on developing an enzyme therapy to treat ENPP1 and ABCC6 Deficiencies, rare genetic diseases associated with significant morbidity, mortality, and unmet medical need.

BioMarin is a world leader in developing and commercializing innovative therapies for rare diseases driven by genetic causes. With a 20-year history, BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored. Visit www.biomarin.com to learn more.

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.